RE: Rebought5 Feb 2022 14:35
It's ref here in the RNS of 16/12/21 :-
London, UK, 16 December 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces a progress update on payer coverage of Accrufer® in the US.
Following the US launch of Accrufer® in July 2021, one of the Company's key focus points was to establish payer coverage. Shield has made substantial progress, successfully securing payer coverage with several large pharmacy benefit managers (PBMs), including Express Scripts and Optum, providing the Company with access to approximately 40 million commercial patients. These contracts result in Accrufer® being placed on formulary1 and are effective immediately.
Shield will provide a further, more detailed business update to shareholders in the first quarter of 2022.